To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants

Completed · Phase 1 · Has a placebo group

Conditions studied: Thrombosis

In brief

Access the safety, tolerability, and pharmacokinetics of BMS-986177 in healthy Japanese participants after multiple doses are administered.

Key facts

Study ID

NCT03224260

Run by

Bristol-Myers Squibb

People needed

33

Starts

2017-06-28

Expected to finish

2017-11-07

Last updated by the study team

2018-06-01

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Participants must be first-generation Japanese (born in Japan and not living outside of Japan for > 10 years; both parents must be ethnically Japanese)
• Body Mass Index 18.0 to 25.0 kg/m2, inclusive
• Women must not be of nonchildbearing potential (cannot become pregnant)

You may not qualify if…

• Any significant acute or chronic medical illness
• History of allergy to BMS-986177 or other factor Xia inhibitors and/or formulation excipients or history of any significant drug allergy (such as anaphylaxis or hepatotoxicity)
• History or evidence of abnormal bleeding or coagulation disorder
• Other protocol defined inclusion and exclusion criteria apply

Where it is running

• West Coast Clinical Trials — Anaheim, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.